Pump thrombosis (PT) is a serious complication after continuous-flow left ventricular assist device (LVAD) implantation. To detect PT, echocardiographic ramp test using left ventricular end-diastolic diameter (LVEDD) is known to be useful. However, this method has several limitations. In this study, we propose an alternative novel ramp test using the flow velocity of outflow graft (OG). A 46-year-old man underwent continuous-flow LVAD (HeartMate II, Abbott Laboratories, Lake Forest, IL, USA) implantation for advanced heart failure due to idiopathic dilated cardiomyopathy. About 2 years after implantation, he suffered from hemolysis and symptoms of heart failure, and PT was strongly suspected. The change in LVEDD was minimal with increase in pump speed (−0.06 cm/400 rotations per minute (rpm)), suggesting PT. The systolic to diastolic velocity (S/D) ratio of OG flow, which we proposed as a new indicator of PT, also showed minimal change (−0.07/400 rpm). His clinical symptoms improved with anticoagulation therapy, and the changing slope of the S/D ratio dramatically improved to −0.92/400 rpm. Although its consistency should be verified in many other cases, this novel method can be useful for detecting PT and evaluating its clinical course.
C ontinuous-flow left ventricular assist device (LVAD) is widely used for patients with advanced heart failure. Pump thrombosis (PT) is a serious complication after implantation, which can cause heart failure due to pump malfunction and hemolysis. 1) Furthermore, it is quite difficult to detect thrombus in the pump.
The usefulness of echocardiographic ramp test to detect PT has been reported. Uriel et al. reported that the changing slope of left ventricular end-diastolic diameter (LVEDD) with increasing pump speed was smaller in PT cases.
2) However, in cases with aortic insufficiency (AI) or elevated blood pressure (BP), this method may become inaccurate, because these conditions can ameliorate the change of LVEDD with increasing pump speed.
3) Furthermore, accurate LVEDD measurement is sometimes difficult because of the reverberation artifact or poor imaging. Therefore, other applicable methods are expected.
Meanwhile, the flow pattern of outflow graft (OG) was reported useful for detecting PT. 4, 5) However, the usefulness of echocardiographic ramp test using OG flow has not been evaluated. Herein, we present a PT case in which echocardiographic ramp test using OG flow was useful for its diagnosis.
Case Report
A 46-year-old man underwent continuous-flow LVAD (HeartMate II, Abbott Laboratories, Lake Forest, IL, USA) implantation for advanced heart failure due to idiopathic dilated cardiomyopathy. After 54 days since LVAD implantation, he was discharged without any complications. Hemoglobin (Hb) was 14.6 g/dL, lactate dehydrogenase (LDH) was 376 U/L, and brain natriuretic peptide (BNP) was 53 pg/mL at the time of discharge. The first echocardiographic ramp test using LVEDD was performed at this time as a routine test. The peak velocity during systole and the lowest velocity during diastole of OG flow at each pump speed were also measured. It was difficult to measure flow velocity of inflow cannula accurately in this case. Parameters were evaluated by changing pump speed at intervals of 400 rotations per minute (rpm). OG flow was measured by pulse Doppler with the right parasternal approach (Table, left About 2 years after implantation, he suffered from hemolysis and symptoms of heart failure (Hb, 8.3 g/dL; LDH, 1180 U/L; BNP, 195 pg/mL; urine blood 3+ without red blood cells in the sediment (hemoglobinuria)), and PT was strongly suspected. Platelet count was decreased from 215 to 141 × 10 3 /μL, which also suggested PT. We performed the second echocardiographic ramp test (Table, middle line). The change in LVEDD was minimal with increase in pump speed, and the changing ratio of LVEDD was −0.06 cm/400 rpm. The systolic to diastolic velocity (S/D) ratio of OG flow, which we proposed as a new index reflecting PT, showed minimal change (−0.07/400 rpm) with increase in pump speed from 8800 rpm to 10800 rpm. The waveform of OG flow also showed minimal change with increasing pump speed (Figures 1, 2) .
The patient was clinically diagnosed with PT, and continuous heparin infusion in addition to warfarin was started. His clinical symptoms gradually improved with aggressive anticoagulation therapy (Hb, 10.3 g/dL; LDH, 288 U/L; BNP, 55 pg/mL). The third echocardiographic ramp test was performed after the improvement of PT (Table, right 
Discussion
In this case report, we clearly showed the usefulness of this novel ramp test using the S/D ratio of OG flow. Furthermore, a serial ramp test was performed, which confirmed that this method is valuable not only for detecting PT but also for evaluating the improvement of PT in a single case. Utility and limitations of echocardiographic ramp test using LVEDD: PT after continuous-flow LVAD implantation occurs in 7% of cases annually.
6) The patients' condition can deteriorate because PT possibly causes pump malfunction and hemolysis. Uriel et al. have proposed the echocardiographic ramp test using LVEDD for detecting PT.
2) The clinical utility of this method was reported by Kato et al., not only for diagnosing PT but also for evaluating the improvement of this life-threatening condition. 7) However, recently, some limitations for this ramp test using LVEDD have been recognized. In cases with AI or elevated BP, patients might be misdiagnosed with PT because these conditions can ameliorate the change in LVEDD with increasing pump speed. 3, 8) Furthermore, accurate LVEDD measurement is sometimes difficult because of the reverberation artifact or poor imaging. There- 4) In PT cases, diastolic velocity of OG flow decreases because it reflects the amount of blood extracted by LVAD, whereas systolic velocity increases because the preload for the LV is elevated. 5) However, there has been no report about the ramp test using OG waveform.
In this case, the S/D ratio of OG flow was 3.7 at the time of PT at baseline pump speed (8800 rpm). However, PT improvement did not show a decrease in the S/D ratio (4.7) at the same pump speed. Considering these results, the S/D ratio itself may be insufficient for detecting PT as it easily changes with volume status or baseline pump speed. Therefore, we believe that ramp test using the S/D ratio of OG flow can be a highly robust and accurate method for detecting PT. As previously described, systolic velocity of OG mainly depends on the contraction of the native heart, whereas diastolic velocity of OG mainly depends on the function of LVAD. 4, 5) Under normal conditions, diastolic velocity increases with the increase of pump speed reflecting the pump function. Systolic velocity may decrease reflecting the decrease of preload. Therefore, the S/D ratio decreases with the increase of pump speed. In contrast, in PT condition, diastolic velocity does not increase, and systolic velocity does not decrease because of the pump malfunction. Therefore, the S/D ratio is expected to remain unchanged in PT condition.
We point out some conceivable limitations for this method. First, we could not evaluate the effect of AI or elevated BP on this new method in this case report because the patient had only trace AI, and BP was well controlled. In this report, ramp test using LVEDD was also useful for the diagnosis of PT. In the future, we will evaluate the superiority of this novel method, especially in cases of AI or high BP. Second, it may be difficult to visualize OG in some cases. Finally, we need to evaluate the utility of this method in devices other than HeartMate II.
In summary, we reported a PT case in which echocardiographic ramp test using the S/D ratio of OG flow was useful for detecting PT. This novel method can be an alternative for conventional ramp test using LVEDD. Moreover, it was useful for the serial evaluation of PT in this single case. Further evaluations of this method for clinical utility are expected.
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